,,ii ,calendar ,no4 #ebj #aaith ,,congress #b;d ,session ,s4 #adad ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,april #aj1 #bjbe,mr4 ,paul 7for himself1 ,mr4 ,lee1 and ,ms4 ,hassan7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,july #bg1 #bjbf,reported by ,mr4 ,cassidy1 with an amendment,strike out all after the enacting clause and insert the part printed in italic ,a ,,bill ,to amend the ,public ,health ,service ,act to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity1 pharmacodynamics1 or comparative clinical efficacy4 #a4 ,short title ,this ,act may be cited as the ,expedited ,access to ,biosimilars ,act4 #b4 ,assessment of immunogenicity1 pharmacodynamics1 or comparative clinical efficacy in clinical studies required for licensure of biological products as biosimilar 7a7 ,in general ,section #cea7k77#b77;,a7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7k77#b77;,a77 is amended-- 7#a7 in clause 7i77,i7-- 7,a7 in item 7bb71 by striking and at the end2 and 7,b7 by striking item 7cc7 and inserting the following 7cc7 a clinical study or studies assessing pharmacokinetics that are sufficient to demonstrate safety1 purity1 and potency2 and 7dd7 subject to clause 7iv71 a clinical study or studies that are sufficient to demonstrate safety1 purity1 and potency in #a or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product2 2 and 7#b7 by adding at the end the following3 7iv7 ,clinical studies 7,i7 ,in general ,subject to subclause 7,,ii71 the ,secretary may determine1 in the ,secretary's discretion1 that a clinical study required under clause 7i77,i77dd7 shall include the assessment of immunogenicity1 pharmacodynamics1 or comparative clinical efficacy4 7,,ii7 ,requirement ,the ,secretary may only require the assessment of immunogenicity1 pharmacodynamics1 or comparative clinical efficacy pursuant to a determination under subclause 7,i7 if the ,secretary provides to the applicant notice of the requirement1 including a written justification of the basis for such determination1 not later than the earliest date on which the applicant may file the application under this subsection4 4 7b7 ,applicability ,the amendments made by subsection 7a7 shall apply with respect to an application submitted under section #cea7k7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7k77 on or after the date of enactment of this ,act4 #a4 ,short title ,this ,act may be cited as the ,expedited ,access to ,biosimilars ,act4 #b4 ,data required for licensure of biological products as biosimilar 7a7 ,in general ,section #cea7k77#b77;,a7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7k77#b77;,a77 is amended-- 7#a7 in clause 7i77,i7-- 7,a7 in item 7bb7-- 7i7 by striking or 7cc7 and inserting 1 7cc71 or 7dd72 and 7ii7 by striking and at the end2 and 7,b7 by striking item 7cc7 and inserting the following 7cc7 an assessment of pharmacokinetics and immunogenicity 7which may rely on1 or consist of1 a clinical pharmacokinetics study or studies described in item 7aa7 or 7dd771 as appropriate2 and 7dd7 a clinical study or studies1 if required by the ,secretary pursuant to clause 7ii77,,ii71 to support a demonstration that there is no clinically meaningful difference between the biological product and the reference product in terms of safety1 purity1 and potency of such product2 2 and 7#b7 in clause 7ii7-- 7,a7 in the clause heading1 by striking ,determination and inserting ,determinations2 7,b7 by striking ,the ,secretary may and inserting the following3 7,i7 ,in general ,the ,secretary may 2 and 7,c7 by adding at the end the following3 7,,ii7 ,procedure for certain studies 7aa7 ,in general ,for an application for licensure of a biosimilar biological product submitted under this subsection1 the ,secretary may require a clinical study that includes an assessment of pharmacodynamics or efficacy1 as described in clause 7i77,i77dd71 only if the ,secretary provides a written determination1 as described in item 7bb7 or 7cc71 to the sponsor of the biosimilar biological product that such assessments or studies are necessary1 in combination with other information required pursuant to clause 7i77,i71 to demonstrate biosimilarity4 7bb7 ,written determination ,the ,secretary shall-- 7,,aa7 when the ,secretary issues meeting minutes of a biosimilar biological product development meeting 7as such term is defined in section #gdd;,g7#e7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act71 provide a written determination described in item 7aa71 or provide written notice to the sponsor that describes why such a determination can not be made at such time2 and 7,,bb7 if the ,secretary is unable to make a written determination described in item 7aa7 at the time described in subitem 7,,aa71 provide such determination not later than #fj days after the date of submission of an application for licensure under this section4 7cc7 ,amendment to a determination ,a written determination under this subclause shall not be amended to require a clinical study or studies described in clause 7i77,i77dd7 after the date on which such a determination is made1 except-- 7,,aa7 by written agreement with the sponsor2 or 7,,bb7 in the case that the ,secretary determines there is a scientific justification to amend the determination1 provides a detailed written justification to the sponsor as soon as practicable1 and1 upon the request of the sponsor1 holds a biosimilar biological product development meeting 7as such term is defined in section #gdd;,g7#e7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act7 to discuss the amendment4 4 7b7 ,streamlining biosimilar reviews ,section #cea7k77#e7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7k77#e77 is amended-- 7#a7 by striking subparagraph 7,b72 and 7#b7 by redesignating subparagraph 7,c7 as subparagraph 7,b74 7c7 ,applicability ,the amendments made by subsections 7a7 and 7b7 shall apply with respect to an application submitted under section #cea7k7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7k77 on or after the date of enactment of this ,act4 ,july #bg1 #bjbf,reported with an amendment